消化指南

订阅

MedSci主页 / 所有栏目 / 消化指南

结直肠癌分子生物标志物检测专家共识

2018-04-10 中华病理学杂志, 2018,47(4) : 237-240.

结直肠癌分子生物标志物

结直肠癌是常见的消化道肿瘤之一，我国的结直肠癌发病率和病死率都居于前列。多数结直肠癌患者在初诊时已属于中晚期，正确的治疗决定患者的预后，结直肠癌疗效预测和预后评估分子标志物的检测结果对临床制订正确的治疗方案非常重要。随着靶向治疗和免疫治疗在结直肠癌治疗中的应用，晚期结直肠癌的治疗进入了一个新的阶段。

中文标题：

结直肠癌分子生物标志物检测专家共识

发布机构：

发布日期：

2018-04-10

简要介绍：

结直肠癌是常见的消化道肿瘤之一，我国的结直肠癌发病率和病死率都居于前列。多数结直肠癌患者在初诊时已属于中晚期，正确的治疗决定患者的预后，结直肠癌疗效预测和预后评估分子标志物的检测结果对临床制订正确的治疗方案非常重要。随着靶向治疗和免疫治疗在结直肠癌治疗中的应用，晚期结直肠癌的治疗进入了一个新的阶段。

制定者：《结直肠癌分子生物标志物检测专家共识》编写组

 

拓展指南：与结直肠癌相关指南：

相关资料下载：
[AttachmentFileName(sort=100, fileName=结直肠癌分子生物标志物检测专家共识)] GetToolGuiderByIdResponse(projectId=1, id=34f741c00158ae8a, title=结直肠癌分子生物标志物检测专家共识, enTitle=, guiderFrom=中华病理学杂志, 2018,47(4) : 237-240., authorId=null, author=, summary=结直肠癌是常见的消化道肿瘤之一，我国的结直肠癌发病率和病死率都居于前列。多数结直肠癌患者在初诊时已属于中晚期，正确的治疗决定患者的预后，结直肠癌疗效预测和预后评估分子标志物的检测结果对临床制订正确的治疗方案非常重要。随着靶向治疗和免疫治疗在结直肠癌治疗中的应用，晚期结直肠癌的治疗进入了一个新的阶段。 , cover=, journalId=null, articlesId=null, associationId=null, associationName=, associationIntro=, copyright=0, guiderPublishedTime=Tue Apr 10 00:00:00 CST 2018, originalUrl=, linkOutUrl=, content=<P>结直肠癌是常见的消化道肿瘤之一，我国的结直肠癌发病率和病死率都居于前列。多数结直肠癌患者在初诊时已属于中晚期，正确的治疗决定患者的预后，结直肠癌疗效预测和预后评估分子标志物的检测结果对临床制订正确的治疗方案非常重要。随着靶向治疗和免疫治疗在结直肠癌治疗中的应用，晚期结直肠癌的治疗进入了一个新的阶段。 </P>制定者：《结直肠癌分子生物标志物检测专家共识》编写组 <P> </P>拓展指南：<strong>与<font color=red>结直肠癌</font>相关指南：</strong><br><ul><li><a href="http://www.medsci.cn/guideline/show_article.do?id=f9fab1c0015e780e" title="NCCN临床实践指南：结直肠癌筛查（2018.V1）" target=_blank>NCCN临床实践指南：结直肠癌筛查（2018.V1）</a></li> <li><a href="http://www.medsci.cn/guideline/show_article.do?id=15c941c0015a8373" title="遗传性结直肠癌临床诊治和家系管理中国专家共识" target=_blank>遗传性结直肠癌临床诊治和家系管理中国专家共识</a></li> <li><a href="http://www.medsci.cn/guideline/show_article.do?id=a70dd1c0015ae5fc" title="结直肠癌肝转移腹腔镜/机器人同期联合切除技术指南（2017修订）" target=_blank>结直肠癌肝转移腹腔镜/机器人同期联合切除技术指南（2017修订）</a></li> <li><a href="http://www.medsci.cn/guideline/show_article.do?id=1a16a1c0015a4555" title="中国结直肠癌诊疗规范（2017版）主要更新概要" target=_blank>中国结直肠癌诊疗规范（2017版）主要更新概要</a></li> <li><a href="http://www.medsci.cn/guideline/show_article.do?id=4e2e11c0015a080b" title="2017 ASER/POQI联合共识声明：加速择期结直肠癌手术康复术后胃肠功能紊乱" target=_blank>2017 ASER/POQI联合共识声明：加速择期结直肠癌手术康复术后胃肠功能紊乱</a></li> 更多信息请点击：<a href="http://www.medsci.cn/guideline/list.do?q=%E7%BB%93%E7%9B%B4%E8%82%A0%E7%99%8C" target=_blank>有关结直肠癌更多指南</a></ul>, tagList=[TagDto(tagId=539, tagName=结直肠癌), TagDto(tagId=74075, tagName=分子生物标志物)], categoryList=[CategoryDto(categoryId=4, categoryName=消化, tenant=100), CategoryDto(categoryId=5, categoryName=肿瘤科, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=null, articleKeyword=null, articleKeywordNum=null, guiderKeywordId=null, guiderKeyword=null, guiderKeywordNum=null, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=共识, guiderLanguage=1, guiderRegion=3, opened=0, paymentType=null, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=12225, appHits=553, showAppHits=0, pcHits=5573, showPcHits=7445, likes=140, shares=26, comments=7, approvalStatus=1, publishedTime=Fri Apr 27 20:13:04 CST 2018, publishedTimeString=2018-04-10, pcVisible=1, appVisible=1, editorId=2020535, editor=qiushida2, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=1, createdBy=null, createdName=qiushida2, createdTime=Fri Apr 27 20:13:04 CST 2018, updatedBy=null, updatedName=null, updatedTime=Sat Jan 06 12:20:42 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=100, fileName=结直肠癌分子生物标志物检测专家共识)])
结直肠癌分子生物标志物检测专家共识
下载请点击：
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1063758, encodeId=fc1a1063e588b, content=好资源，学习一下, beContent=null, objectType=guider, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/H3QXYibjbzM9C5GELMGhjqMatvmOsXy5gzoqIT6XJqYYCg7BqyfaLVW7gmk0bjAUJygFZUxt3XakaHUP7VIGDww/132, createdBy=a1285314326, createdName=taken110, createdTime=Mon Oct 25 14:33:47 CST 2021, time=2021-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=316980, encodeId=9fb831698054, content=学习了.但好像没有把每种情况说清, beContent=null, objectType=guider, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9e092140152, createdName=345lihongxia, createdTime=Sun May 20 19:41:57 CST 2018, time=2018-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=316038, encodeId=96c53160381a, content=学习啦, beContent=null, objectType=guider, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a4932112798, createdName=1871f9015am, createdTime=Thu May 17 15:23:54 CST 2018, time=2018-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=310385, encodeId=05ba3103857f, content=学习了.谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/10/23/557c1f19aaf5459a8405411e38903c4b.jpg, createdBy=dfc02088287, createdName=cscdliu, createdTime=Sun Apr 29 11:18:24 CST 2018, time=2018-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=310268, encodeId=44ec3102680c, content=学习了.谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Sun Apr 29 06:16:17 CST 2018, time=2018-04-29, status=1, ipAttribution=)]
    2021-10-25 taken110

    好资源，学习一下

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1063758, encodeId=fc1a1063e588b, content=好资源，学习一下, beContent=null, objectType=guider, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/H3QXYibjbzM9C5GELMGhjqMatvmOsXy5gzoqIT6XJqYYCg7BqyfaLVW7gmk0bjAUJygFZUxt3XakaHUP7VIGDww/132, createdBy=a1285314326, createdName=taken110, createdTime=Mon Oct 25 14:33:47 CST 2021, time=2021-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=316980, encodeId=9fb831698054, content=学习了.但好像没有把每种情况说清, beContent=null, objectType=guider, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9e092140152, createdName=345lihongxia, createdTime=Sun May 20 19:41:57 CST 2018, time=2018-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=316038, encodeId=96c53160381a, content=学习啦, beContent=null, objectType=guider, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a4932112798, createdName=1871f9015am, createdTime=Thu May 17 15:23:54 CST 2018, time=2018-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=310385, encodeId=05ba3103857f, content=学习了.谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/10/23/557c1f19aaf5459a8405411e38903c4b.jpg, createdBy=dfc02088287, createdName=cscdliu, createdTime=Sun Apr 29 11:18:24 CST 2018, time=2018-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=310268, encodeId=44ec3102680c, content=学习了.谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Sun Apr 29 06:16:17 CST 2018, time=2018-04-29, status=1, ipAttribution=)]
    2018-05-20 345lihongxia

    学习了.但好像没有把每种情况说清

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1063758, encodeId=fc1a1063e588b, content=好资源，学习一下, beContent=null, objectType=guider, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/H3QXYibjbzM9C5GELMGhjqMatvmOsXy5gzoqIT6XJqYYCg7BqyfaLVW7gmk0bjAUJygFZUxt3XakaHUP7VIGDww/132, createdBy=a1285314326, createdName=taken110, createdTime=Mon Oct 25 14:33:47 CST 2021, time=2021-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=316980, encodeId=9fb831698054, content=学习了.但好像没有把每种情况说清, beContent=null, objectType=guider, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9e092140152, createdName=345lihongxia, createdTime=Sun May 20 19:41:57 CST 2018, time=2018-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=316038, encodeId=96c53160381a, content=学习啦, beContent=null, objectType=guider, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a4932112798, createdName=1871f9015am, createdTime=Thu May 17 15:23:54 CST 2018, time=2018-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=310385, encodeId=05ba3103857f, content=学习了.谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/10/23/557c1f19aaf5459a8405411e38903c4b.jpg, createdBy=dfc02088287, createdName=cscdliu, createdTime=Sun Apr 29 11:18:24 CST 2018, time=2018-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=310268, encodeId=44ec3102680c, content=学习了.谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Sun Apr 29 06:16:17 CST 2018, time=2018-04-29, status=1, ipAttribution=)]
    2018-05-17 1871f9015am

    学习啦

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1063758, encodeId=fc1a1063e588b, content=好资源，学习一下, beContent=null, objectType=guider, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/H3QXYibjbzM9C5GELMGhjqMatvmOsXy5gzoqIT6XJqYYCg7BqyfaLVW7gmk0bjAUJygFZUxt3XakaHUP7VIGDww/132, createdBy=a1285314326, createdName=taken110, createdTime=Mon Oct 25 14:33:47 CST 2021, time=2021-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=316980, encodeId=9fb831698054, content=学习了.但好像没有把每种情况说清, beContent=null, objectType=guider, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9e092140152, createdName=345lihongxia, createdTime=Sun May 20 19:41:57 CST 2018, time=2018-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=316038, encodeId=96c53160381a, content=学习啦, beContent=null, objectType=guider, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a4932112798, createdName=1871f9015am, createdTime=Thu May 17 15:23:54 CST 2018, time=2018-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=310385, encodeId=05ba3103857f, content=学习了.谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/10/23/557c1f19aaf5459a8405411e38903c4b.jpg, createdBy=dfc02088287, createdName=cscdliu, createdTime=Sun Apr 29 11:18:24 CST 2018, time=2018-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=310268, encodeId=44ec3102680c, content=学习了.谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Sun Apr 29 06:16:17 CST 2018, time=2018-04-29, status=1, ipAttribution=)]
    2018-04-29 cscdliu

    学习了.谢谢

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1063758, encodeId=fc1a1063e588b, content=好资源，学习一下, beContent=null, objectType=guider, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/H3QXYibjbzM9C5GELMGhjqMatvmOsXy5gzoqIT6XJqYYCg7BqyfaLVW7gmk0bjAUJygFZUxt3XakaHUP7VIGDww/132, createdBy=a1285314326, createdName=taken110, createdTime=Mon Oct 25 14:33:47 CST 2021, time=2021-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=316980, encodeId=9fb831698054, content=学习了.但好像没有把每种情况说清, beContent=null, objectType=guider, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9e092140152, createdName=345lihongxia, createdTime=Sun May 20 19:41:57 CST 2018, time=2018-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=316038, encodeId=96c53160381a, content=学习啦, beContent=null, objectType=guider, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a4932112798, createdName=1871f9015am, createdTime=Thu May 17 15:23:54 CST 2018, time=2018-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=310385, encodeId=05ba3103857f, content=学习了.谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/10/23/557c1f19aaf5459a8405411e38903c4b.jpg, createdBy=dfc02088287, createdName=cscdliu, createdTime=Sun Apr 29 11:18:24 CST 2018, time=2018-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=310268, encodeId=44ec3102680c, content=学习了.谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Sun Apr 29 06:16:17 CST 2018, time=2018-04-29, status=1, ipAttribution=)]
    2018-04-29 1209e435m98(暂无昵称)

    学习了.谢谢分享

    0

相关指南

中国结直肠癌诊疗规范（2017版）主要更新概要

暂未更新 · 2018-01-10

中国结直肠癌诊疗规范（2017版）

中华人民共和国国家卫生和计划生育委员会(NHFPC,National Health and Family Planning Commission of China) · 2017-12-15

结直肠癌腹膜转移诊治中国专家意见（2017）

中国医师协会结直肠肿瘤专委会 腹膜肿瘤专业委员会 · 2017-10-30

2017 NICE诊断指南：结直肠癌患者林奇综合征分子检测策略（DG.27）

暂未更新 · 2017-02-22

2017 ASER/POQI联合共识声明：优化镇痛加速结直肠癌手术康复（二）

美国促进恢复学会(ASER,American Society for Enhanced Recovery) · 2017-04-13

2017 ASER/POQI联合共识声明：优化镇痛加速结直肠癌手术康复（一）

美国促进恢复学会(ASER,American Society for Enhanced Recovery) · 2017-04-13